Related Experiment Video
Updated: Mar 17, 2026
07:38
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
895
Context, Context, Context: New Gene Programs Linked to Bad Behavior in MLL-AF9-Initiated Leukemia
Tatsuro Watanabe1, Patricia Ernst1
1Division of Hematology, Oncology and Bone Marrow Transplant, Department of Pediatrics, University of Colorado, Denver/Anschutz Medical Campus, 12800 East 19th Avenue, MS #8302, Aurora, CO 80045, USA.
Cancer Cell
|July 15, 2016
Summary
The MLL-AF9 fusion drives acute myelogenous leukemia (AML) with varied behaviors. Researchers found a transcriptional signature similar to epithelial-to-mesenchymal transition, linked to disease aggressiveness.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Acute myelogenous leukemia (AML) is a heterogeneous blood cancer.
- Gene fusions, such as MLL-AF9, are key drivers in certain leukemias.
- Understanding the molecular basis of AML subtypes is crucial for treatment.
Purpose of the Study:
- To investigate the impact of MLL-AF9 fusion expression on AML development and behavior.
- To identify molecular signatures associated with MLL-AF9-driven AML aggressiveness.
Main Methods:
- Analysis of gene expression profiles in MLL-AF9-driven AML models.
- Comparison of transcriptional signatures with known cellular processes.
- Correlation of molecular signatures with disease characteristics.
Main Results:
- MLL-AF9 expression leads to AML with context-dependent behaviors.
- A distinct transcriptional signature was identified in MLL-AF9 AML.
- This signature unexpectedly resembles the epithelial-to-mesenchymal (EMT) transition.
Conclusions:
- Cell context significantly influences MLL-AF9-driven AML phenotype.
- The EMT-like transcriptional signature correlates with AML aggressiveness.
- This finding offers potential new avenues for understanding and targeting aggressive AML.
Related Concept Videos
02:23Abnormal Proliferation
5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
01:06Induced Pluripotent Stem Cells
6.0K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
6.0K
01:15Differentiation of Common Myeloid Progenitor Cells
4.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.2K
03:03mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K
02:07Tumor Progression
7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K